Open Access“Chronic myelogenous leukemia in primary blast crisis” rather than “de novo BCR ‐ ABL 1 ‐positive acute myeloid leukemia”
Author(s) -
Pastoret Cedric,
Houot Roch
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.937
Subject(s) - basophilia , chronic myelogenous leukemia , medicine , blast crisis , philadelphia chromosome , myeloid leukemia , breakpoint cluster region , leukemia , cancer research , immunology , chromosomal translocation , biology , receptor , genetics , gene
Key Clinical Message Differentiating chronic myelogenous leukemia in primary blast crisis ( CML ‐ BC ) from de novo BCR ‐ ABL 1 ‐positive acute myeloid leukemia ( AML ) is a diagnostic challenge with therapeutic consequences. In our case, a basophilia, the presence of the Philadelphia chromosome in all metaphases and the strict exclusion of molecular hallmarks of AML lead us to retain the diagnosis of CML ‐ BC rather than BCR ‐ ABL 1+ AML .